COVID-19 Research
In response to the COVID-19 pandemic, the Wellstar Research Institute has actively supported research projects, which will both provide cutting edge treatment options and answer important questions surrounding COVID-19 and its impact on physical and psychological health.
Quality Improvement Projects
COVID-19 Clinical Practice Evaluation, Dr. David Snipelisky, Cardiology
Quantification of moral distress in nurses during the COVID-19 pandemic, Steven Shields, JD, Medical Ethics
Databases
Critical Care Management of COVID-19, Dr. Sean Lee, Cardiology
Acute Encephalopathy in Critically Ill Patients with SARS-COV-2 Infection, Dr. Michael Mendoza, Neuroscience
COVID/Cardiology Database, Dr. Rajinish Prasad, Cardiology
Exempt Studies
Decontamination and Reuse of N95 Respirators with Ultraviolet Germicidal Irradiation (UVGI) to Address Personal Protective Equipment Shortages During COVID-19 Pandemic, LeeAnna Spiva, PhD, Nursing Administration
Active Clinical Trials
Sponsor: Mayo Clinic
Study/Agent: Convalescent Plasma
Sites: AMC Main, AMC South, Cobb, Douglas, Kennestone, North Fulton, Paulding, Spalding and West Georgia
Status: Active and enrolling
Sponsor: Regeneron
Study/Agent: Sarulimab
Sites: Kennestone
Status: Active and enrolling
Sponsor: CytoDyn
Study/Agent: Leronlimab Compassionate Use
Sites: All sites eligible
Status: Active, single-patient compassionate use. eIND from FDA and notification to Wellstar IRB required before each use.
Sponsor: Gilead
Study/Agent: Remdesivir Emergency Use Authorization (EUA)
Sites: All sites eligible
Status: EUA designation replaces the need for discrete eINDs from FDA and notification to Wellstar IRB required before each use.
Pending Research
Late Disease Complications of Hospital-Diagnosed COVID-10 Patients on Follow-Up in Primary Care: A Longitudinal Case-Control Study, Dr. Earl Stewart, Family Medicine
National Registry for Surveillance and Epidemiology of Perinatal COVID-19 Infection, Dr. Jessica Daigle, Pediatrics
Pending Clinical Trials
Sponsor: Regeneron
Study/Agent: Safety/Efficacy of anti-spike SARS-CoV-2 monoclonal antibodies in hospitalized patients with COVID-19
Sites: Undetermined
Status: Pending
Sponsor: Regeneron
Study/Agent: Safety/Efficacy of anti-spike SARS-CoV-2 antibodies in ambulatory patients with COVID-19
Sites: Undetermined
Status: Pending
Sponsor: Regeneron
Study/Agent: Safety/Efficacy of anti-spike SARS-CoV-2 antibodies in first responders and healthcare workers
Sites: Undetermined
Status: Pending
Sponsor: Vivacor-Eurofins
Study/Agent: Detection of SARS-CoV-2 by rRT-PCR in saliva versus NP swab
Sites: Kennestone
Status: Pending
Sponsor: Romark
Study/Agent: Safety/Efficacy nitazoxanide for post exposure prophylaxis of COVID-19 in healthcare workers
Sites: Undetermined
Status: Pending
Sponsor: ICTAL Group
Study/Agent: NEURO-COVID - COVID-related encephalopathy database
Sites: All sites eligible
Status: Pending
Sponsor: University of Missouri
Study/Agent: COVID/HIV database
Sites: Kennestone
Status: Pending
Sponsor: R-Pharm International
Study/Agent: Safety/Efficacy of olokizumab in patients with severe COVID-19 infection
Sites: Undetermined
Status: Pending
Sponsor: CSL Behring
Study/Agent: Safety/Efficacy of CSL312 and CSL324 monoclonal antibodies for diffuse alveolar damage in COVID-19
Sites: Undetermined
Status: Pending
Sponsor: Wellstar
Study/Agent: Hyperbaric Oxygen Therapy (HBOT) for COVID-19 infection
Sites: North Fulton
Status: Pending
Sponsor: Wellstar
Study/Agent: COVID-19 long-term F/U
Sites: All sites
Status: Pending
Sponsor: Wellstar
Study/Agent: Clinical outcomes of hospitalized COVID-19 patients treated with Remdesivir—a prospective open-label observational study
Sites: All sites
Status: Pending